Downstaging and Survival Associated with Neoadjuvant Immunotherapy Before Radical Cystectomy for Muscle-invasive Bladder Cancer

Grassauer, Jacob; Schmidt, Jackson; Cowan, Andrew J.; Gilbert, Scott M.; Chakiryan, Nicholas H.

doi:10.1016/j.euo.2023.06.005

Cited by 4 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using a propensity score matching method, Grassauer et al. ( 49 ) reported the survival and outcome of 840 patients who had surgery alone (n=280), neoadjuvant chemotherapy (n-=280), and neoadjuvant immunotherapy (n=280) for their locally advanced bladder cancer. The pCR rate was 26.4% and 22.5% for the neoadjuvant chemotherapy and immunotherapy, respectively.…”

Section: Rationale For Using Immunotherapy In Bladder Cancermentioning

confidence: 99%

Immunotherapy and radiotherapy for older patients with invasive bladder cancer unfit for surgery or chemotherapy: practical proposal by the international geriatric radiotherapy group

Nguyen,

Karlsson,

Page

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

The standard of care for non-metastatic muscle invasive bladder cancer is either radical cystectomy or bladder preservation therapy, which consists of maximal transurethral bladder resection of the tumor followed by concurrent chemoradiation with a cisplatin-based regimen. However, for older cancer patients who are too frail for surgical resection or have decreased renal function, radiotherapy alone may offer palliation. Recently, immunotherapy with immune checkpoint inhibitors (ICI) has emerged as a promising treatment when combined with radiotherapy due to the synergy of those two modalities. Transitional carcinoma of the bladder is traditionally a model for immunotherapy with an excellent response to Bacille Calmette-Guerin (BCG) in early disease stages, and with avelumab and atezolizumab for metastatic disease. Thus, we propose an algorithm combining immunotherapy and radiotherapy for older patients with locally advanced muscle-invasive bladder cancer who are not candidates for cisplatin-based chemotherapy and surgery.

show abstract

Section: Rationale For Using Immunotherapy In Bladder Cancermentioning

confidence: 99%